Insight Molecular Diagnostics Inc (IMDX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$2.46-7.17%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · IMDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 93.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -60.0% |
Growth built into the price is above our model estimate.
The price assumes 153.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 19 industry peers
IMDX — divestiture
Dated 2026-09-21
Entry into a Material Definitive Agreement. As previously reported, Insight Molecular Diagnostics Inc. (the “Company” or “iMDx”) entered into an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Merger Agreement”), by and among the Company, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), Chronix, the stockholders party to the Merge…
Why it matters: The company has little kit revenue so far. Large orders would show that transplant centers are starting to use the product.
Supportive ifAfter FDA approval, iMDx reports a large U.S. GraftAssureDx kit order from a transplant center or reference lab.
Worry ifThe company reports no large U.S. kit orders in the first two earnings reports after FDA approval.
Why it matters: Cash use exceeded management's 2026 target in both reported quarters. Lower cash use would give the company more time to launch its test.
Worry ifQuarterly cash from operations stays above $6 million of outflow in the second half of 2026.
Less concerning ifQuarterly cash from operations falls to $6 million of outflow or less in the second half of 2026.
Why it matters: The registry tests the company's combined score in kidney transplant patients. More centers would add to its clinical evidence.
Supportive ifThe company reports that 50 or more U.S. transplant centers have joined the GALACTIC registry.
Worry ifThe registry has fewer than 34 centers. Or the company says center enrollment has stopped growing.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$320 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,090 loss on $10,000 · 10.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,099 loss on $10,000 · 71.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.